Aurobindo Pharma arm bags USFDA nod for Pemetrexed for Injection

 Alone, as maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.

 Alone, for treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy.

Read also: Aurobindo Pharma acquires domestic formulation business of Veritaz for Rs 171 crore

The approved product has an estimated market size of US$ 1272 million for the twelve months ending March 2022, according to IQVIA. This is the 139 th ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.

The company has 26 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA.

Read also: Aurobindo Pharma arm bags USFDA nod for cancer drug Bortezomib